Published in Hypertension on May 27, 2003
Interleukin 17 promotes angiotensin II-induced hypertension and vascular dysfunction. Hypertension (2009) 3.06
CD4+CD25+Foxp3 regulatory T cells and vascular dysfunction in hypertension. J Hypertens (2013) 2.07
A role for angiotensin II type 1 receptors on bone marrow-derived cells in the pathogenesis of angiotensin II-dependent hypertension. Hypertension (2009) 1.94
Stimulation of lymphocyte responses by angiotensin II promotes kidney injury in hypertension. Am J Physiol Renal Physiol (2008) 1.71
Chronic ANG II infusion induces sex-specific increases in renal T cells in Sprague-Dawley rats. Am J Physiol Renal Physiol (2014) 1.43
Renal inflammation, autoimmunity and salt-sensitive hypertension. Clin Exp Pharmacol Physiol (2012) 1.15
Toll-like receptors and damage-associated molecular patterns: novel links between inflammation and hypertension. Am J Physiol Heart Circ Physiol (2013) 1.08
Amelioration of 2,4,6-trinitrobenzene sulphonic acid induced colitis in angiotensinogen gene knockout mice. Gut (2005) 1.04
Renal oxidative stress, oxygenation, and hypertension. Am J Physiol Regul Integr Comp Physiol (2011) 1.02
Renal tubulointerstitial hypoxia: cause and consequence of kidney dysfunction. Clin Exp Pharmacol Physiol (2011) 0.99
Immune and inflammatory role in renal disease. Compr Physiol (2013) 0.97
Angiotensin II, Aldosterone, and Anti-Inflammatory Lymphocytes: Interplay and Therapeutic Opportunities. Int J Hypertens (2012) 0.97
Reciprocal interaction between macrophages and T cells stimulates IFN-γ and MCP-1 production in Ang II-induced cardiac inflammation and fibrosis. PLoS One (2012) 0.96
Dual opposing roles of adaptive immunity in hypertension. Eur Heart J (2014) 0.95
Immune Mechanisms in Arterial Hypertension. J Am Soc Nephrol (2015) 0.94
The immunological basis of hypertension. Am J Hypertens (2014) 0.94
T cell immunity and cardiovascular metabolic disorders: does metabolism fuel inflammation? Front Immunol (2012) 0.90
Role of T lymphocytes in angiotensin II-mediated microvascular thrombosis. Hypertension (2011) 0.90
Sex differences in T cells in hypertension. Clin Ther (2014) 0.89
Female spontaneously hypertensive rats have a compensatory increase in renal regulatory T cells in response to elevations in blood pressure. Hypertension (2014) 0.89
Angiotensin II is a new component involved in splenic T lymphocyte responses during Plasmodium berghei ANKA infection. PLoS One (2013) 0.87
IL-1β and IL-18: inflammatory markers or mediators of hypertension? Br J Pharmacol (2014) 0.86
Spontaneous white matter damage, cognitive decline and neuroinflammation in middle-aged hypertensive rats: an animal model of early-stage cerebral small vessel disease. Acta Neuropathol Commun (2014) 0.86
Interleukin-2/Anti-Interleukin-2 Immune Complex Expands Regulatory T Cells and Reduces Angiotensin II-Induced Aortic Stiffening. Int J Hypertens (2014) 0.83
ETA activation mediates angiotensin II-induced infiltration of renal cortical T cells. J Am Soc Nephrol (2011) 0.82
The role of type 1 angiotensin receptors on T lymphocytes in cardiovascular and renal diseases. Curr Hypertens Rep (2013) 0.81
Differential phenotypes of tissue-infiltrating T cells during angiotensin II-induced hypertension in mice. PLoS One (2014) 0.81
The peptide network regulated by angiotensin converting enzyme (ACE) in hematopoiesis. Cell Cycle (2011) 0.81
Gut Microbiota Promote Angiotensin II-Induced Arterial Hypertension and Vascular Dysfunction. J Am Heart Assoc (2016) 0.81
Valsartan Attenuates Atherosclerosis via Upregulating the Th2 Immune Response in Prolonged Angiotensin II-Treated ApoE(-/-) Mice. Mol Med (2015) 0.80
Perivascular adipose tissue inflammation in vascular disease. Br J Pharmacol (2017) 0.79
Immunomodulation strategies for preventing vascular disease of the brain and heart: workshop summary. Stroke (2006) 0.79
Irreversible renal damage after transient renin-angiotensin system stimulation: involvement of an AT1-receptor mediated immune response. PLoS One (2013) 0.78
The effect of renin-angiotensin system blockade on the incidence of end-stage renal disease in IgA nephropathy. Clin Exp Nephrol (2015) 0.77
Chronic angiotensin receptor blockade suppresses intracardiac angiotensin II in angiotensin II-infused rats. Exp Biol Med (Maywood) (2011) 0.77
Immunosuppression-Independent Role of Regulatory T Cells against Hypertension-Driven Renal Dysfunctions. Mol Cell Biol (2015) 0.77
Dysregulation of T cell subsets in the pathogenesis of hypertension. Curr Hypertens Rep (2015) 0.76
Angiotensin II in inflammation, immunity and rheumatoid arthritis. Clin Exp Immunol (2015) 0.75
Angiotensin II synergizes with BAFF to promote atheroprotective regulatory B cells. Sci Rep (2017) 0.75
Angiotensin converting enzyme activity in alopecia areata. Enzyme Res (2014) 0.75
Immunologic Effects of the Renin-Angiotensin System. J Am Soc Nephrol (2017) 0.75
Angiotensin II Promotes the Development of Carotid Atherosclerosis in Type 2 Diabetes Patients via Regulating the T Cells Activities: A Cohort Study. Med Sci Monit (2016) 0.75
Circulating Th1, Th2, and Th17 Levels in Hypertensive Patients. Dis Markers (2017) 0.75
Klotho converts canonical FGF receptor into a specific receptor for FGF23. Nature (2006) 9.40
Targeted ablation of Fgf23 demonstrates an essential physiological role of FGF23 in phosphate and vitamin D metabolism. J Clin Invest (2004) 7.00
FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis. J Bone Miner Res (2003) 6.81
The intrarenal renin-angiotensin system: from physiology to the pathobiology of hypertension and kidney disease. Pharmacol Rev (2007) 6.79
The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2009). Hypertens Res (2009) 5.24
The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2014). Hypertens Res (2014) 4.83
Increased circulatory level of biologically active full-length FGF-23 in patients with hypophosphatemic rickets/osteomalacia. J Clin Endocrinol Metab (2002) 4.17
Health-related quality of life as a predictor of mortality and hospitalization: the Dialysis Outcomes and Practice Patterns Study (DOPPS). Kidney Int (2003) 3.90
Predictors and consequences of altered mineral metabolism: the Dialysis Outcomes and Practice Patterns Study. Kidney Int (2005) 3.56
Association of comorbid conditions and mortality in hemodialysis patients in Europe, Japan, and the United States: the Dialysis Outcomes and Practice Patterns Study (DOPPS). J Am Soc Nephrol (2003) 3.53
Direct evidence for a causative role of FGF23 in the abnormal renal phosphate handling and vitamin D metabolism in rats with early-stage chronic kidney disease. Kidney Int (2010) 3.04
Mechanical stress activates angiotensin II type 1 receptor without the involvement of angiotensin II. Nat Cell Biol (2004) 3.03
Mutant FGF-23 responsible for autosomal dominant hypophosphatemic rickets is resistant to proteolytic cleavage and causes hypophosphatemia in vivo. Endocrinology (2002) 3.00
Evaluation of new acute kidney injury biomarkers in a mixed intensive care unit. Crit Care Med (2011) 2.68
Nonadherence in hemodialysis: associations with mortality, hospitalization, and practice patterns in the DOPPS. Kidney Int (2003) 2.65
Impaired flow-dependent control of vascular tone and remodeling in P2X4-deficient mice. Nat Med (2005) 2.59
FGF-23 transgenic mice demonstrate hypophosphatemic rickets with reduced expression of sodium phosphate cotransporter type IIa. Biochem Biophys Res Commun (2004) 2.52
Combination of two urinary biomarkers predicts acute kidney injury after adult cardiac surgery. Ann Thorac Surg (2012) 2.39
Modification of mineralocorticoid receptor function by Rac1 GTPase: implication in proteinuric kidney disease. Nat Med (2008) 2.25
Epigenetic modulation of the renal β-adrenergic-WNK4 pathway in salt-sensitive hypertension. Nat Med (2011) 2.18
Vitamin D receptor-independent FGF23 actions in regulating phosphate and vitamin D metabolism. Am J Physiol Renal Physiol (2005) 2.05
Diuretic use, residual renal function, and mortality among hemodialysis patients in the Dialysis Outcomes and Practice Pattern Study (DOPPS). Am J Kidney Dis (2007) 2.03
Hemoglobin is expressed by mesangial cells and reduces oxidant stress. J Am Soc Nephrol (2008) 1.99
Renal L-type fatty acid--binding protein in acute ischemic injury. J Am Soc Nephrol (2007) 1.98
Salt-induced nephropathy in obese spontaneously hypertensive rats via paradoxical activation of the mineralocorticoid receptor: role of oxidative stress. Hypertension (2007) 1.93
Association between activating mutations of calcium-sensing receptor and Bartter's syndrome. Lancet (2002) 1.89
In vivo klotho gene transfer ameliorates angiotensin II-induced renal damage. Hypertension (2002) 1.88
Health-related quality of life among dialysis patients on three continents: the Dialysis Outcomes and Practice Patterns Study. Kidney Int (2003) 1.86
QTL mapping of domestication-related traits in soybean (Glycine max). Ann Bot (2007) 1.85
Sleep quality predicts quality of life and mortality risk in haemodialysis patients: results from the Dialysis Outcomes and Practice Patterns Study (DOPPS). Nephrol Dial Transplant (2007) 1.85
Mortality among hemodialysis patients in Europe, Japan, and the United States: case-mix effects. Am J Kidney Dis (2004) 1.84
Association of eNOS Glu298Asp polymorphism with end-stage renal disease. Hypertension (2002) 1.83
Effects of NADPH oxidase inhibitor in diabetic nephropathy. Kidney Int (2005) 1.78
The receptor of advanced glycation end products plays a central role in advanced oxidation protein products-induced podocyte apoptosis. Kidney Int (2012) 1.77
Plasminogen activator inhibitor-1 antagonist TM5441 attenuates Nω-nitro-L-arginine methyl ester-induced hypertension and vascular senescence. Circulation (2013) 1.76
Endoplasmic reticulum stress induces autophagy in renal proximal tubular cells. Nephrol Dial Transplant (2009) 1.76
Anti-FGF23 neutralizing antibodies show the physiological role and structural features of FGF23. J Bone Miner Res (2008) 1.75
Blockade of the nuclear factor-κB pathway in the endothelium prevents insulin resistance and prolongs life spans. Circulation (2012) 1.75
Urinary L-type fatty acid-binding protein as a new biomarker of sepsis complicated with acute kidney injury. Crit Care Med (2010) 1.74
Expression and cellular localization of classic NADPH oxidase subunits in the spontaneously hypertensive rat kidney. Hypertension (2002) 1.73
Protective effect of potassium against the hypertensive cardiac dysfunction: association with reactive oxygen species reduction. Hypertension (2006) 1.71
Effect of sevelamer and calcium-based phosphate binders on coronary artery calcification and accumulation of circulating advanced glycation end products in hemodialysis patients. Am J Kidney Dis (2011) 1.69
Oxidative stress and nitric oxide synthase in rat diabetic nephropathy: effects of ACEI and ARB. Kidney Int (2002) 1.68
Changes in anemia management and hemoglobin levels following revision of a bundling policy to incorporate recombinant human erythropoietin. Kidney Int (2010) 1.67
Renoprotective properties of angiotensin receptor blockers beyond blood pressure lowering. J Am Soc Nephrol (2005) 1.64
Therapeutic effects of anti-FGF23 antibodies in hypophosphatemic rickets/osteomalacia. J Bone Miner Res (2009) 1.63
Kidney hypoxia, attributable to increased oxygen consumption, induces nephropathy independently of hyperglycemia and oxidative stress. Hypertension (2013) 1.63
Critical protection from renal ischemia reperfusion injury by CD55 and CD59. J Immunol (2004) 1.61
Importance of endothelial NF-κB signalling in vascular remodelling and aortic aneurysm formation. Cardiovasc Res (2012) 1.61
IRBIT, an inositol 1,4,5-trisphosphate receptor-binding protein, specifically binds to and activates pancreas-type Na+/HCO3- cotransporter 1 (pNBC1). Proc Natl Acad Sci U S A (2006) 1.61
Induction of renoprotective gene expression by cobalt ameliorates ischemic injury of the kidney in rats. J Am Soc Nephrol (2003) 1.60
siRNA-based therapy ameliorates glomerulonephritis. J Am Soc Nephrol (2010) 1.58
A novel mutation in fibroblast growth factor 23 gene as a cause of tumoral calcinosis. J Clin Endocrinol Metab (2005) 1.56
Methylglyoxal induces peritoneal thickening by mesenchymal-like mesothelial cells in rats. Nephrol Dial Transplant (2008) 1.56
Podocyte injury underlies the glomerulopathy of Dahl salt-hypertensive rats and is reversed by aldosterone blocker. Hypertension (2006) 1.55
Isolation and potential existence of side population cells in adult human kidney. Int J Urol (2008) 1.55
Anti-albuminuric effect of the aldosterone blocker eplerenone in non-diabetic hypertensive patients with albuminuria: a double-blind, randomised, placebo-controlled trial. Lancet Diabetes Endocrinol (2014) 1.55
Venous sampling for fibroblast growth factor-23 confirms preoperative diagnosis of tumor-induced osteomalacia. J Clin Endocrinol Metab (2004) 1.54
Glutamate receptor antagonists and benzodiazepine inhibit the progression of granule cell dispersion in a mouse model of mesial temporal lobe epilepsy. Epilepsia (2005) 1.53
Hyperostosis-hyperphosphatemia syndrome: a congenital disorder of O-glycosylation associated with augmented processing of fibroblast growth factor 23. J Bone Miner Res (2007) 1.52
Evidence of tubular hypoxia in the early phase in the remnant kidney model. J Am Soc Nephrol (2004) 1.52
Antioxidant, EUK-8, prevents murine dilated cardiomyopathy. Circ J (2009) 1.52
Metallothionein is upregulated by hypoxia and stabilizes hypoxia-inducible factor in the kidney. Kidney Int (2008) 1.52
Inhibition of histone deacetylase activity suppresses epithelial-to-mesenchymal transition induced by TGF-beta1 in human renal epithelial cells. J Am Soc Nephrol (2006) 1.51
Paradoxical mineralocorticoid receptor activation and left ventricular diastolic dysfunction under high oxidative stress conditions. J Hypertens (2008) 1.49
Enhanced aldosterone signaling in the early nephropathy of rats with metabolic syndrome: possible contribution of fat-derived factors. J Am Soc Nephrol (2006) 1.49
Improving outcomes for dialysis patients in the international Dialysis Outcomes and Practice Patterns Study. Clin J Am Soc Nephrol (2006) 1.47
Hypophosphatemia induced by intravenous administration of saccharated ferric oxide: another form of FGF23-related hypophosphatemia. Bone (2009) 1.47
The suffocating kidney: tubulointerstitial hypoxia in end-stage renal disease. Nat Rev Nephrol (2010) 1.46
Parathyroid hormone-related protein induced coupled increases in bone formation and resorption markers for 7 years in a patient with malignant islet cell tumors. J Bone Miner Res (2002) 1.44
Endogenous prostaglandin D2 synthesis reduces an increase in plasminogen activator inhibitor-1 following interleukin stimulation in bovine endothelial cells. J Hypertens (2002) 1.43
Podocyte as the target for aldosterone: roles of oxidative stress and Sgk1. Hypertension (2007) 1.43
Prognosis and risk factors for idiopathic membranous nephropathy with nephrotic syndrome in Japan. Kidney Int (2004) 1.42
Human herpesvirus 6B infection of the large intestine of patients with diarrhea. Clin Infect Dis (2002) 1.40
Cobalt promotes angiogenesis via hypoxia-inducible factor and protects tubulointerstitium in the remnant kidney model. Lab Invest (2005) 1.38
Lung injury following acute kidney injury: kidney-lung crosstalk. Clin Exp Nephrol (2011) 1.38
Inhibition of hydroxymethylglutaryl-coenzyme a reductase reduces Th1 development and promotes Th2 development. Circ Res (2003) 1.38
Wrong primer for rat angiotensinogen mRNA. Am J Physiol Renal Physiol (2005) 1.38
Report of the Working Group for Dietary Salt Reduction of the Japanese Society of Hypertension: (2) Assessment of salt intake in the management of hypertension. Hypertens Res (2007) 1.37
Functional polymorphisms in the vascular endothelial growth factor gene are associated with development of end-stage renal disease in males. J Am Soc Nephrol (2006) 1.37
Urinary free fatty acids bound to albumin aggravate tubulointerstitial damage. Kidney Int (2002) 1.37